COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD), a biopharmaceutical company, today announced that Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES) has received $1.3 million under a previously awarded U.S. Office of Naval Research grant for the treatment and prevention of decompression sickness (DCS) with Oxycyte™. Oxycyte is Synthetic Blood’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. Synthetic Blood has begun the process of manufacturing and shipping Oxycyte to VCURES for use in these studies.
